35 GATEHOUSE DRIVE, WALTHAM, MA
Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Reports Preliminary 2025 Financial Highlights and Provides Business Updates at the 44th Annual J.P. Morgan Healthcare Conference
Board Approves Amendments to Bylaws; Uncertificated Shares Effective December...
Reports Third Quarter 2025 Financial Results and Provides Business Update
FDA Approval of Revuforj® (revumenib) in Adult and Pediatric Patients with Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia
Investor Presentation
Changes in Board, Management or Compensation
Changes in Board, Management or Compensation, Reg. FD
FY 2024
Q3
Q2
Q1
Registration Statement for Securities to be Offered to Employees
S-3ASR
Prospectus filed pursuant to Rule 424(b)(5)
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Schedule 13G - Ownership Report